Literature DB >> 7631139

Enhancement of interleukin-6 production by fibrinogen degradation product D in human peripheral monocytes and perfused murine liver.

J Mandl1, M Csala, I Léránt, G Bánhegyi, J Biró, R Machovich, A Falus.   

Abstract

The effect of fibrinogen degradation products D and E (FDP-D, FDP-E) on IL-6 production in perfused mouse livers and peripheral monocytes is studied. Similarly to bacterial endotoxin FDP-D is highly potent to augment the IL-6 production measured in perfused mouse livers, while FDP-E is not stimulatory. FDP-D but not FDP-E is able to stimulate the in vitro IL-6 production of human peripheral monocytes, as well. Plasmin alone is almost ineffective on IL-6 production both in perfused livers and monocytes. Our findings suggest a direct positive feedback circuit, among fibrinogen, FDP and IL-6.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631139     DOI: 10.1111/j.1365-3083.1995.tb03642.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

Review 1.  Inflammation, coagulation, and the pathway to frailty.

Authors:  Bindu Kanapuru; William B Ershler
Journal:  Am J Med       Date:  2009-07       Impact factor: 4.965

2.  Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cells.

Authors:  Fang Guo; Jun-Tian Liu; Chen-Jing Wang; Xiao-Ming Pang
Journal:  Inflamm Res       Date:  2011-11-17       Impact factor: 4.575

3.  African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension.

Authors:  M Khaleghi; U Saleem; R D McBane; T H Mosley; I J Kullo
Journal:  J Thromb Haemost       Date:  2008-10-30       Impact factor: 5.824

4.  Haemostatic markers are associated with measures of vascular disease in adults with hypertension.

Authors:  M Khaleghi; L A Singletary; V Kondragunta; K R Bailey; S T Turner; T H Mosley; I J Kullo
Journal:  J Hum Hypertens       Date:  2009-01-29       Impact factor: 3.012

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.